ECCO 2023

New molecules on the horizon!

A focus on surgery and post-operative maintenance

JAK inhibitors - small molecules to treat IBD

No impact of previous therapies for Upadacitinib in…

Upadacitinib works in bionaive and bio-exposed pts in…

Prolonged treatment with Ozanimod recaptures remission…

S1P modulators in UC

Upadacitinib for fistulizing Crohn´s disease?

Mucosal healing induced by vedolizumab in chronic…

Medium-term outcome of IBD patients diagnosed at…

Long-term extension of ustekinumab in UC

Upadacitinib is efficacious for UC regardless of…

Long-term duration of response with ozanimod in UC

Latest update on JAK inhibition

Η μεσοπρόθεσμη έκβαση ασθενών με ΙΦΝΕ που…

Lang Termijn respons met ozanimod bij colitis ulcerosa

Il prolungamento del trattamento con Ozanimod induce…

Update zu JAK-Inhibitoren bei CED

Upadacitinib: Vortherapien spielen keine Rolle mehr bei…

Studio lungo termine di ustekinumab in UC

Upadacitinib is efficient bij colitis ulcerosa,…

New aspects on safety of anti-TNF treatment

Anti-IL23 drugs: is it all the same?

S1P-modulators: a spotlight on safety

Etrasimod shows fast stool frequency and rectal…

Ileostomy with better prognosis than pouch in PSC

Positive effects of Upadacitinib on resolution of…

Risk of IBD from early antibiotic exposure in live

Ozanimod shows good efficacy and safety profile after…

Les antibiotiques dans la petite enfance augmentent le…

Το upadacitinib επιφέρει ύφεση των κοιλιακών…

Rapido controllo del sanguinamento rettale e della…

Practice-changing data on surgery in CD and UC

Another clue for the role of the microbiome in PSC?

Enteral nutrition - food for thought!

Surgical and post-operative management in CD

Vedolizumab prevents postoperative recurrence in CD

Surgery in CD - resetting or not?

DNA methylation predicts response to biologics in IBD

Vedolizumab for preventing postoperative reccurence of…

Is it feasible to stop anti-TNF treatment in…

Timing of surgery in Crohn's disease

Peri- and postoperative management of CD

Early treatment with biologics in IBD

Biologics in CD – is earlier better?

New drugs on the block!

Epigenetic fingerprinting - a novel tool for precision…

Ileocaecal Crohn's disease - should we call the surgeon…

Post-surgical Crohn's disease

Neue Substanzen!

Biosimilars

Aanpak van de (post)operatieve Crohn patient

Another clue for the role of the microbiome in PSC?

Vedolizumab previene la recidiva post operatoria nei…

Peri- und postoperatives Management bei Morbus Crohn

Postać ileocekalna choroby Crohna - czy chirurgia ma…

Epigenetic Fingerprinting - ein neues Werkzeug für die…

Résection chirurgicale au course de la maladie de…

Είναι ευχερές να διακόψουμε τους αντι-TNF παράγοντες…

Résection chirurgicale précoce dans la MC

Vedolizumab en prévention de la récidive postopératoire…

Chirurgischer Verlauf nach Morbus Crohn

Comprehensive remission - the new standard!?

Comprehensive Disease Control

Our patients will be better off in the near future!

GPX4 fueling postoperative recurrence in Crohn's…

New ECCO guidelines on extraintestinal manifestations…

Mucosal signatures suggest a mechanism for early CD…

New opportunities from the application of artificial…

Comprehensive overview of surgery in IBD

Sequencing nelle malattie infiammatorie cronicale…

Nuove opportunità dall’applicazione dell’intelligenza…

Una vida mejor en el futuro inmediato para nuestros…

Panoramica completa sulla chirurgia nelle malattie…

GPX4 fördert postoperatives Morbus Crohn Rezidiv

Nowe wytyczne ECCO dotyczące manifestacji…